Flavonols and cardiovascular disease

Francisco Perez-Vizcaino, Juan Duarte

Abstract

Flavonols, and specially quercetin, are widely distributed in plants and are present in considerable amounts in fruits and vegetables. In addition to their anti-oxidant effect, flavonols interfere with a large number of biochemical signaling pathways and, therefore, physiological and pathological processes. There is solid evidence that, in vitro, quercetin and related flavonols exert endothelium-independent vasodilator effects, protective effect on nitric oxide and endothelial function under conditions of oxidative stress, platelet antiaggregant effects, inhibition of LDL oxidation, reduction of adhesion molecules and other inflammatory markers and prevention of neuronal oxidative and inflammatory damage. The metabolites of quercetin show partial protective effects on endothelial function and LDL oxidation. Quercetin produces undisputed antihypertensive and antiatherogenic effects, prevents endothelial dysfunction and protects the myocardium from ischemic damage. It has no clear effects on serum lipid profile and on insulin resistance. Human intervention trials with isolated flavonols demonstrate an antihypertensive effect. The meta-analysis of epidemiological studies show an inverse association between flavonol (together with flavone) intake and coronary heart disease and stroke. Therefore, although there is no solid proof yet, a substantial body of evidence suggests that quercetin may prevent the most common forms of cardiovascular disease contributing to the protective effects afforded by fruits and vegetables.

© 2010 Elsevier Ltd. All rights reserved.

Contents

1. Introduction ................................................................. 479
2. Flavonols, the endothelium and the vascular smooth muscle ........................................ 480
3. Flavonols and platelets ................................................ 483
4. Flavonols and hypertension ........................................ 484
5. Flavonols and atherosclerosis ..................................... 485
6. Flavonols, insulin resistance and obesity ...
   6.1. Obesity ................................................................. 486
   6.2. Insulin resistance ................................................. 487
7. Flavonols and myocardial ischemia .......................... 489
8. Flavonols and stroke .................................................. 490
9. Conclusions ............................................................... 490
1. Introduction

Flavonoids were discovered in the 1930s and were initially considered vitamins (“vitamin P”) for their effect on capillary permeability (Rusznyak and Szent-Györgyi, 1936). The interest in these compounds decayed after they were shown not to be required as micronutrients for human health in the 1940s (Joint-Committee-Nomenclature-ASBC-AIN, 1950). However, a large expansion of the field took place much later, in the 1990s, after the publication of epidemiological studies associating a reduced incidence of cancer and cardiovascular disease with a greater intake of flavonoids (Hertog et al., 1993; Keli et al., 1996). Today above 30,000 studies have been published with flavonoids and above 10,000 with a single one of them: quercetin (Fig. 1). The major advances in the research about flavonols in the cardiovascular field are summarized in Table 1.

Flavonoids constitute a large class of polyphenols found in plants. This group includes several subclasses, such as flavonols, flavones, flavanones, flavanols, anthocyanidins, isoflavones, dihydroflavonols and chalcones (Fig. 2). Among flavonoids, flavonols (together with flavanols) are by far the most abundant and widely distributed in nature. Flavonols are present, usually as diverse glycosides, in considerable amounts in our normal diet. Although flavonols can be found virtually in all

![Figure 1](image)

**Fig. 1.** Trend of publications containing the word “quercetin” in the abstract in the last 30 years analyzed from data in the ISI Web of Science.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Major advances in the research of flavonols in the cardiovascular field.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Discovery of flavonols and effects on capillary permeability</td>
<td>Rusznyak and Szent-Györgyi (1936)</td>
</tr>
<tr>
<td>Platelet antiaggregant effects of quercetin</td>
<td>Beretz et al. (1982)</td>
</tr>
<tr>
<td>Flavonols inhibit NADPH oxidase and scavenge superoxide</td>
<td>Tauber et al. (1984), Busse et al. (1984)</td>
</tr>
<tr>
<td>Quercetin prevents oxidized-LDL cytotoxicity</td>
<td>Negre-Salvayre and Salvayre (1992)</td>
</tr>
<tr>
<td>Inverse association between flavonol and flavone intake with coronary heart disease</td>
<td>Hertog et al. (1993)</td>
</tr>
<tr>
<td>Quercetin and wine polyphenols inhibit LDL oxidation</td>
<td>Frankel et al. (1993)</td>
</tr>
<tr>
<td>Vasodilator effects of quercetin</td>
<td>Duarte et al. (1993a), Fitzpatrick et al. (1993)</td>
</tr>
<tr>
<td>Inverse association between flavonol and flavone intake with stroke</td>
<td>Keli et al. (1996)</td>
</tr>
<tr>
<td>Antiatherosclerotic effects of wine polyphenols and quercetin</td>
<td>Hayek et al., (1997)</td>
</tr>
<tr>
<td>Antihypertensive effects of quercetin</td>
<td>Duarte et al. (2001b)</td>
</tr>
<tr>
<td>Quercetin and other polyphenolics activate sirtuins</td>
<td>Howitz et al. (2003)</td>
</tr>
<tr>
<td>Antihypertensive effects of quercetin in humans</td>
<td>Edwards et al. (2007)</td>
</tr>
<tr>
<td>Meta-analysis of epidemiological studies with flavonols and stroke</td>
<td>Hollman et al. (2010)</td>
</tr>
</tbody>
</table>
vegetables and fruits, the richest sources include onions, apples, cider, grapes, wine and tea. They derive from 3-hydroxyflavone, the simplest flavonol. The prototypical flavonol is quercetin, the most abundant in plants and the best studied. Other common flavonols include kaempferol, myricetin, isorhamnetin, tamarixetin, morin and fisetin (Fig. 2). Kaempferol and myricetin are also present in many foods. Isorhamnetin and tamarixetin are methylated metabolites of quercetin and they are usually found in plasma or tissues after quercetin consumption. The daily intake of flavonols has been estimated as 20–35 mg/d, of which more than 65% is quercetin and its glycosides. The bioavailability of quercetin depends on the nature of its attached sugars and the components of the food matrix (ethanol, fat, and emulsifiers) which may affect its solubility. For example, the intake of onions leads to a higher quercetin plasma levels than other dietary sources (Davalos et al., 2006). Glucosides from onions are a better source of bioavailable quercetin than the aglycone given as a pure compound (Hollman et al., 1995). However, when a food source rich in glucosides (shallot flesh) was compared with one rich in the aglycones (the dried shallot skin), the latter led to a higher quercetin plasma levels, indicating that the food matrix is a key factor for quercetin bioavailability (Wiczkowski et al., 2008).

Flavonols show a wide range of biological activities, being the most active compounds within the flavonoids group. Thus, the beneficial effects of diets rich in fruits and vegetables on cardiovascular health have been often attributed to flavonoids in general and more specifically to flavonols. Flavonols are commercialized as dietary supplements either as pure compounds (e.g. quercetin), flavonoids mixtures or extracts, often at doses that exceed by far the dietary intake. Some flavonoids are also used as venotonic drugs for the treatment of several venous diseases (Lyseng-Williamson and Perry, 2003).

In this paper, we will review the continuously growing evidence supporting a beneficial role of flavonols on cardiovascular disease and the potential molecular targets involved. Most of the studies were carried out with quercetin. The available data indicate qualitatively similar biological effects of kaempferol, isorhamnetin and tamarixetin. Myricetin shares with the other flavonols some of their actions but may produce differential and sometimes opposite effects. There is also a vast number of interesting studies using dietary sources, medicinal plants or flavonoid extracts in which the actions may be attributed to flavonols but also to other flavonoids or other substances which will not be addressed herein.

An interesting issue which has been the focus of attention in recent years is whether the observations made in vitro with quercetin and other flavonols have any relevance in vivo. The biological activity of flavonoids has been analyzed using commercially available aglycones (not glycosylated) compounds which are present at extremely low concentrations in plasma (Kroon et al., 2004). Quercetin is rapidly conjugated with glucuronic acid and/or sulfate during first-pass metabolism (intestine–liver) and a portion of the metabolites are also methylated and, therefore, the major metabolites of quercetin in human plasma are quercetin-3-glucuronide, quercetin-3-sulfate and isorhamnetin-3-glucuronide. The limited information available about the in vitro effects of these metabolites will also be reviewed herein. In general, these metabolites are less active than the parent compounds and sometimes totally inactive. However, it is also becoming evident that conjugated metabolites can be deconjugated by beta-glucuronidase and flavonol aglycones can accumulate in tissues (Bieger et al., 2008). There is some indirect evidence that the activity of quercetin glucuronides depends on their deconjugation (Lee-Hilz et al., 2008).

2. Flavonols, the endothelium and the vascular smooth muscle

The vascular endothelium exerts a fine control of cardiovascular homeostasis. The equilibrium between vasodilators and vasoconstrictors, prothrombotic and antithrombotic factors and proliferative and antiproliferative factors is shifted in
cardiovascular diseases leading to hypertension, atherosclerosis, platelet aggregation and ischemia. Thus, endothelial dysfunction is characterized by impaired endothelium-dependent vasodilation, reduced NO activity and a prothrombotic and proinflammatory state of endothelial cells. Endothelial dysfunction is an early and independent predictor of poor prognosis in most forms of cardiovascular diseases (Schachinger et al., 2000; Widlansky et al., 2003). Thus, alterations in endothelial function have been consistently found in hypertension, atherosclerosis, coronary heart disease, diabetes, sepsis, obesity and aging.

The effects of quercetin and related flavonoids modulating endothelial function and dysfunction has been widely studied (Perez-Vizcaino et al., 2006b). Quercetin exerts direct acute vasodilator effects in isolated arteries (Fig. 3) (Duarte et al., 1993a,b; Fitzpatrick et al., 1993). In healthy vessels, these effects are endothelium-independent and occur similarly, albeit with different potency, in arteries constricted by different stimuli. Interestingly, quercetin and its methylated metabolites are more potent in coronary arteries (Ibarra et al., 2002) and in resistance than in conductance vessels (Perez-Vizcaino et al., 2002) and also in vessels from hypertensive animals (Ibarra et al., 2003). Endothelium- and NO-dependent relaxation has been reported for several isolated flavonoids, especially the anthocyanin delphinidin (Andriambeloson et al., 1998) and the flavone chrysin (Duarte et al., 2001a). These effects are related to a pro-oxidant effect because it can be inhibited by superoxide dismutase and catalase and a subsequent increased in endothelial cytosolic Ca²⁺ levels (Andriambeloson et al., 1998). Some groups have also described that the effects of quercetin are partially endothelium-dependent and related to the release of endothelium-derived relaxing factors (Ajay et al., 2003; Khoo et al., 2010). A pro-oxidant mechanism involving the release of H₂O₂ has been proposed (Khoo et al., 2010). We have also observed increased ROS production by quercetin in rat coronary arteries which could be inhibited by catalase (Cogolludo et al., 2007). ROS production may result from the auto-oxidation of quercetin in the incubation medium or by a specific event occurring in vascular cells. However, we have not observed so far endothelium-dependent relaxation by quercetin in many different vessels studied; an observation consistent with recent data from other groups (Suri et al., 2010). In addition, the glucuronidated and sulfated metabolites of quercetin lack a direct vasodilator effect in the rat aorta (Lodi et al., 2009). In the porcine coronary artery, quercetin 3'-sulfate inhibited endothelin-1 and U46619-induced contractions in an endothelium-independent manner, while quercetin 3-glucoronide was inactive (Suri et al., 2010). We have also noted that quercetin 3'-sulfate has acute vasodilator effects in rat mesenteric resistance arteries, but again with a lower potency than quercetin (unpublished observations). In contrast to quercetin and other flavonoids, myricetin can induce an endothelium-dependent contractile response via an increase in cyclooxygenase-derived vasoconstrictor metabolites (Jimenez et al., 1999).

The actions of quercetin on NO are very complex and the conditions of oxidative stress strongly influence the outcome. In cell-free systems quercetin can be oxidized by oxygen and generate O₂⁻ which rapidly reacts and inactivates NO (Lopez-Lopez et al., 2004) an effect which is not shared by the glucuronidated and sulfated metabolites (Lodi et al., 2008). In endothelial cells in the absence of oxidative stress, quercetin has been reported to increase NO when measured by an amperometric electrode (Taubert et al., 2002) and to increase cytosolic Ca²⁺ measured by fura2 via a pro-oxidant mechanism (Khoo et al., 2010). However, some caution should be taken because due to the redox and fluorescent properties of quercetin (Nifli et al., 2007), interferences with the measuring systems cannot be ruled out. In contrast, when NO production was measured by electron paramagnetic resonance spectroscopy, quercetin failed to increase NO in endothelial cells (Stoclet et al., 1999). Inhibitory effects on eNOS activity in bovine endothelial cells have also been reported (Jackson and Venema, 1999). Thus, in the absence of oxidative stress either increases or decreases in NO can be observed.

In contrast, under conditions of high O₂⁻ and thus accelerated NO metabolism, quercetin can protect NO in a number of ways. First, in cell-free systems when O₂⁻ is increased enzymatically or chemically, quercetin can scavenge O₂⁻ and thus...
protect NO (Lopez-Lopez et al., 2004) (Fig. 4). Second, in cells, quercetin may not only scavenge O\textsubscript{2}• but also inhibit its enzymatic sources, i.e. xanthine oxidase and NADPH oxidase (Busse et al., 1984; Tauber et al., 1984). The glucuronidated and sulfated metabolites can prevent, albeit less effectively than quercetin, the impaired NO bioavailability under conditions of high oxidative stress (Lodi et al., 2009). Third, due to its anti-oxidant properties, flavonoids can potentially avoid BH\textsubscript{4} oxidation and eNOS uncoupling (Romero et al., 2009). Finally, quercetin can inhibit signaling pathways leading to induction of p47\textsuperscript{phox}, a NADPH oxidase subunit. Thus, quercetin can prevent the NO impairment induced by angiotensin II (Sanchez et al., 2007) and endothelin-1 (Romero et al., 2009). The preventive effect of quercetin on endothelial dysfunction induced by endothelin-1 seems to be related to down-regulation of p47\textsuperscript{phox} through PKC inhibition (Romero et al., 2009). The metabolite quercetin-3-glucuronide also prevented endothelin-1–induced endothelial dysfunction (Lodi et al., 2009). In addition, quercetin in vitro restored the impaired endothelial function in arteries from hypertensive (SHR) (Ibarra et al., 2003) and diabetic rats (Ajay et al., 2006).

NO exerts its vasodilator effects by activating soluble guanylyl cyclase in vascular smooth muscle cells and the subsequent increase in cGMP. In turn, cGMP is metabolized by cyclic nucleotide phosphodiesterases (PDEs) and thus, NO activity and endothelium–dependent relaxation are strongly dependent on PDE activity. Therefore, PDE inhibitors can prevent endothelial dysfunction in some circumstances (Vlachopoulos et al., 2004). Several flavonoids have also been reported to inhibit several PDE isoforms (Picq et al., 1989). Thus, inhibition of PDEs may represent another potential mechanism for flavonoid-induced prevention of endothelial dysfunction. In addition, quercetin and its sulfated metabolite selectively enhanced cyclic-GMP-dependent relaxations by a mechanism not involving phosphodiesterase 5 inhibition (Suri et al., 2010). Interestingly, quercetin and the metabolite also prevented nitroglycerine tolerance in vitro (Suri et al., 2010), an effect shared with other O\textsubscript{2}• scavengers (Munzel et al., 1999).

Besides NO, endothelium-derived endothelial factor (EDHF) is another important regulator of vascular function, especially in resistance arteries. The nature of EDHF, depending on the type of artery considered, has been proposed to be epoxyeicosatrienoic acid (EET), potassium or H\textsubscript{2}O\textsubscript{2} and smooth muscle cell hyperpolarization can also be transmitted from the endothelial cells via myoendothelial gap junctions (Feletou and Vanhoutte, 2009). The vasodilator effects of quercetin have been recently reported to be prevented by charybdotoxin, a blocker of intermediate (IK\textsubscript{Ca}) and large (BK\textsubscript{Ca}) conductance K\textsuperscript{+} channels (Khoo et al., 2010). The authors concluded that quercetin releases endothelium-derived hyperpolarizing factor (EDHF) whose activity is dependent on activation of K\textsuperscript{+} channels. We think that this conclusion is not supported by the data. The effect shown by Khoo et al. cannot be attributed to EDHF because (1) charybdotoxin alone does not, or just weakly, inhibit EDHF responses; it must be used in combination with apamin (Corriu et al., 1996) and (2) when arteries are contracted by high concentrations of KCl, as this was the case (70 mM), the membrane potential and the equilibrium potential for potassium approach and therefore, opening or closing K\textsuperscript{+} channels would not affect net flow of K\textsuperscript{+} across the membrane nor membrane potential (Quast and Cook, 1989). In fact, high KCl is often used to inhibit EDHF responses. However, part of endothelium-independent relaxant responses can be attributed to an activation of BK\textsubscript{Ca} channels directly in the arterial smooth muscle cells (Cogolludo et al., 2007).

Endothelin-1 is a potent vasoconstritor released by endothelial cells. Endothelial dysfunction is associated with elevation of endothelin-1 (Brunner et al., 2006). Moreover, ET-1 is able to induce endothelial dysfunction. Quercetin is able to

---

**Fig. 4.** Quercetin protects NO from superoxide-induced degradation. Superoxide was generated by xanthine oxidase plus hypoxanthine (XO) or by pyrogallol (Pyr). The right panel shows the rate constant (K\textsubscript{obs}) for NO dissapearance in the buffer. Reprinted with permission (Lopez-Lopez et al., 2004).
inhibit ET-1 release in human endothelial umbilical vein and in the bovine aortic endothelial cells (Khan et al., 2002; Zhao et al., 1999). In vivo, quercetin also reduced urinary ET-1 in the ApoE knockout mice (Loke et al., 2010) and in healthy men (Loke et al., 2008).

In vivo, a high dose of quercetin added to the diet led to increased NOS activity in the aortic wall of healthy rats without changes in the eNOS expression which was accompanied by increased endothelium-dependent relaxation (Benito et al., 2002). We have also observed a weak but occasionally significant increase in endothelium-dependent relaxation in normotensive WKY rats treated with low doses quercetin (Duarte et al., 2001b). In healthy men quercetin increased plasma S-nitrosothiols, plasma nitrite, and urinary nitrate concentrations, indirectly pointing to increased endothelial NO (Loke et al., 2008). However, quercetin can still induce antihypertensive effects in vivo when NO synthesis is inhibited (the L-NAME model of hypertension as discussed below).

Hypertensive animals, as well as human essential hypertensive patients, develop reduced endothelium derived NO-dependent vasodilatation. In different experimental rat models of hypertension (SHR, DOCA-salt and Goldblatt rats), chronic quercetin restored the impaired endothelial vasodilator function as measured by the relaxant response to acetylcholine (Duarte et al., 2001b; Galisteo et al., 2004; Garcia-Saura et al., 2005; Sanchez et al., 2006). Increased urinary NOx (nitrites + nitrates, main NO metabolites) was also found. All these models were associated with increased plasma, vascular and hepatic oxidative status as measured by plasma, tissue and urinary levels of either malondialdehyde or isoprostanates, and quercetin consistently reduced these parameters (Duarte et al., 2001b; Galisteo et al., 2004; Garcia-Saura et al., 2005; Sanchez et al., 2006). Altogether these results suggest a role for reduced O2−-driven NO inactivation. Furthermore, in SHR which show upregulated eNOS but with a paradoxical reduction in NOS activity compared to their normotensive WKY controls, quercetin normalized both parameters (Sanchez et al., 2006). In addition, as mentioned above for in vitro experiments with angiotensin II and endothelin-1, in SHR quercetin can prevent the upregulation of p47phox (Sanchez et al., 2006). Moreover, chronic quercetin also reduced several markers of endothelial dysfunction in ApoE knockout mice (Loke et al., 2010) and in rats treated with a high-fat high-sucrose diet (Yamamoto and Oue, 2006).

In contrast to the endothelium-dependent vasodilatation to acetylcholine, the endothelium-dependent relaxations to insulin which are also impaired in SHR were unaffected after chronic treatment with quercetin (Romero et al., 2010). The different profile of quercetin against the relaxations induced by these two endothelial NO-releasing agents, despite its protective effect on O2−-driven NO inactivation, might be related to the different pathways of acetylcholine and insulin to activate eNOS. Acetylcholine is a classic cholinergic agonist that activates eNOS by a calcium-dependent mechanism. However, insulin has calcium-independent vasodilator actions that are mediated by a PI3-K dependent mechanism involving phosphorylation of eNOS by Akt (Montagnani et al., 2001). Insulin-stimulated Akt and eNOS phosphorylations were reduced in aortic rings from SHR and WKY rats treated with quercetin. This effect might be related to a direct inhibitory effect of quercetin on PI3-K (Yoshizumi et al., 2002).

Additionally, apparent changes in endothelial-dependent vasodilatation may occur as a consequence of the opposing effects of the release of endothelium-derived vasoconstrictor prostanoids. Chronic quercetin did not modify the endothelium-dependent vasoconstriction in SHR (Duarte et al., 2001b) but markedly inhibited it in NO-deficient (Duarte et al., 2002) and in Goldblatt rats (Garcia-Saura et al., 2005).

The sirtuins Sir2 and its mammalian analog SIRT1 have been implicated in the extended lifespan induced by caloric restriction (Cohen et al., 2004) and more recently in the prevention of vascular senescence (Ota et al., 2010). Activation of SIRT1 has been shown to promote endothelium-dependent vasodilatation (Mattagajasingh et al., 2007) and to downregulate angiotensin II receptor expression (Miyazaki et al., 2008). The discovery of the role of sirtuins in oxidative stress and lifespan has led to a new and fascinating area of research in the field of polyphenols since several polyphenols, including quercetin can activate sirtuins (Howitz et al., 2003). In fact, quercetin extends the lifespan of the yeast Saccharomyces cerevisiae and the worm Caenorhabditis elegans (Belinha et al., 2007; Pietsch et al., 2009).

It should be also mentioned that quercetin inhibits endothelial proliferation and migration and tube formation (Ahn et al., 2009; Igura et al., 2001; Jackson and Venema, 2006). This effect is associated with decreased VEGF expression and might result in reduced angiogenesis in vivo (Luo et al., 2008). Therefore, it might play a role in the chemopreventive effects of quercetin against solid tumors. Several studies have shown that quercetin and its conjugated glucuronide inhibit proliferation and hypertrophy or induce apoptosis in vascular smooth muscle cells in culture (Moon et al., 2003; Perez-Vizcaíno et al., 2006a; Yoshizumi et al., 2002). The inhibitory effects of quercetin on DNA synthesis of vascular smooth muscle cells stimulated by TNF-α appear to be related to reduced ERK1/2 activity, a kinase playing a major role in cell proliferation and differentiation (Moon et al., 2003). In angiotensin II-stimulated vascular smooth muscle cells and in smooth muscle cells with an intimal phenotype (Perez-Vizcaíno et al., 2006a), quercetin inhibit hypertrophy via down-regulation of the JNK pathway (Perez-Vizcaíno et al., 2006a; Yoshizumi et al., 2002). These effects may also account for the antihypertensive and antiatherosclerotic effect of quercetin.

3. Flavonoids and platelets

The platelet antiaggregant effects of flavonoids were initially described by Beretz et al. (1982). Several molecular mechanisms have been proposed to be involved. It was initially suggested that these effects were due to their inhibitory effects on cyclic nucleotide phosphodiesterases and therefore to increased cyclic AMP. Gryglewski et al. described the superoxide...
scavenging actions of flavonols in platelets which would “resuscitate biosynthesis and action of endothelial prostacyclin and EDRF”, accounting for their antithrombotic effects (Gryglewski et al., 1987). Later, it was found that quercetin inhibited PKC-dependent NADPH oxidase activation in platelets (Pignatelli et al., 2006). More recently, the antiaggregant effects were associated to blocking Fyn kinase activity and the tyrosine phosphorylation of Syk and phospholipase Cγ (Wright et al., 2010). However, the in vivo antiaggregant effects of quercetin have been questioned. In a human study with onions providing 114 mg quercetin per day no changes were found on platelet aggregation, thromboxane B2 production, factor VII, or other haemostatic variables (Janssen et al., 1998).

4. Flavonols and hypertension

Hypertension is one of the most powerful risk factor for cardiovascular events, including myocardial infarction and stroke. Treatment with any commonly used antihypertensive regimen reduces the risk of total major cardiovascular events; the larger the reductions in blood pressure the larger reductions in risk (Turnbull, 2003). Under rigorously controlled experimental conditions, fruit and vegetable consumption is associated with a decrease in blood pressure (Dauchet et al., 2009). However, the effects of fruit and vegetables on plasma lipid levels, diabetes, and body weight are unclear yet (Dauchet et al., 2009). We have recently reviewed the role of quercetin as antihypertensive (Perez-Vizcaino et al., 2009). Therefore, we will only briefly summarize and update the information with some recent studies.

The first report on the antihypertensive effects of quercetin was carried out in spontaneously hypertensive rats (SHR), a genetic model of multifactorial hypertension (Duarte et al., 1993b) (Fig. 5). This study was confirmed and extended by others (Carlstrom et al., 2007; Machha and Mustafa, 2005; Romero et al., 2010; Sanchez et al., 2006) and followed by other reports in other classical rat models of experimental hypertension such as hypertension induced by inhibition of NO synthase with L-NAME (Duarte et al., 2002), the deoxycorticosterone acetate-salt hypertensive rats (Galisteo et al., 2004), the two-kidney, one-clip (2K1C) Goldblatt hypertensive rats (Garcia-Saura et al., 2005), Dahl salt-sensitive rats (Aoi et al., 2004; Mackraj et al., 2008) and in hypertensive rats with aortic constriction (Jalili et al., 2006). Moreover, quercetin also lowered blood pressure in animal models of insulin resistance and metabolic syndrome such as the Obese Zucker rat (Rivera et al., 2008b) and in rats fed with a high-fat high-sucrose diet (Yamamoto and Oue, 2006). Therefore, quercetin has demonstrated antihypertensive effects when given chronically in the most common rodent models of hypertension. The dose most frequently used is 10 mg/kg per day, but the effective doses used range from 2 to 300 mg/kg per day. The antihypertensive effect was dose-dependent and affects the systolic, the diastolic and the mean blood pressure. This effect usually starts during the first week of treatment and it is sustained during the treatment period. Interestingly, the reduction in blood pressure is long lasting, remaining at least after 48 h of discontinuation of treatment. Remarkably, quercetin was effective in all models of hypertension analyzed, independently of the origin of the hypertension, the status of renin–angiotensin system, oxidative stress, nitric oxide, and other factors. However, quercetin does not exert hypotensive effects, i.e. it has no effect in control normotensive animals.

According to the so-called “Barker hypothesis”, strongly supported by animal and human epidemiological studies, many adult chronic diseases, including type 2 diabetes, obesity and hypertension may originate in fetal life due to changes in

![Fig. 5. Antihypertensive effects of quercetin in spontaneously hypertensive rats. Reprinted with permission (Duarte et al., 2001a).](image-url)
genetic programming (Barker, 1998). Thus, adult offspring of rats or mice fed with a high fat diet during pregnancy exhibited adult hyperglycemia, insulin resistance, obesity, and hypertension, despite being fed with a standard diet throughout post-natal life (Buckley et al., 2005). Recently, a very interesting study (Liang et al., 2009b) showed that these effects were reduced by supplementing the mice with quercetin during pregnancy (Fig. 6). These results suggest that quercetin can prevent the epigenetic programming during the pre-natal life.

Sustained high blood pressure is one of the most powerful determinants of the development of cardiac, vascular and renal diseases. Most of the benefits of antihypertensive treatment on end-organ damage are the result of lowered blood pressure per se and are largely independent of the drugs or class of drugs employed (Turnbull, 2003). Quercetin has demonstrated a reduction of left ventricular hypertrophy in SHR (Duarte et al., 1993b), the deoxycorticosterone acetate-salt hypertensive rats (Galisteo et al., 2004), the two-kidney, one-clip (2K1C) Goldblatt hypertensive rats (Garcia-Saura et al., 2005), and in hypertensive rats with aortic constriction (Jalili et al., 2006). The flavonol also produced protective effects on renal structure and function in the animal models of hypertension such the NO-deficient rats (Duarte et al., 2002), the deoxycorticosterone acetate-salt hypertensive rats (Galisteo et al., 2004), the two-kidney, one-clip (2K1C) Goldblatt hypertensive rats (Garcia-Saura et al., 2005), and the Dahl salt-sensitive rats (Aoi et al., 2004; Mackraj et al., 2008). The protective effect on endothelial function in these animal models has been mentioned above.

Two randomized, double-blind, placebo-controlled, crossover clinical trials analyzing the effects of quercetin on blood pressure have been recently published. In the study of Edwards et al. (2007), patients with stage 1 hypertension had a reduction in systolic, diastolic and mean arterial pressures after quercetin treatment but the flavonol had no significant effect in pre-hypertensives. In the study of Egert et al. (2010), patients with metabolic syndrome were classified according to their apoE phenotypes. Quercetin decreased systolic blood pressure in the apoE3 group, whereas no significant effect was observed in patients with the apoE4 phenotype. In addition, quercetin had no effect on lipid profile in ApoE3 carriers but exerted a deleterious effect in the ApoE4 subgroup with decreased serum HDL cholesterol and increased the LDL:HDL cholesterol ratio. In another study, carried out in healthy volunteers (Conquer et al., 1998) quercetin intake did not significant modify selected cardiovascular risk factors including blood pressure. Nonetheless, this lack of effect in healthy humans may not be surprising given the lack of effect of quercetin in healthy animals as described above.

5. Flavonols and atherosclerosis

Atherosclerosis is a multifactorial disease characterized by arterial wall thickening caused by deposition of fatty materials over many years. Symptoms become apparent acutely in the late stages of the disease. Alteration in the serum lipid profile is an early and crucial event in the development of atherosclerosis. Oxidative stress, inflammation, and endothelial dysfunction are associated with the pathogenesis of atherosclerosis.

Consumption of low doses of quercetin reduced the progression of atherosclerosis in ApoE-deficient mice (Hayek et al., 1997; Loke et al., 2010). Interestingly, quercetin was more effective than other representative flavonoids ([(-)-epicatechin
[flavan-3-ol], theaflavin (dimeric catechin)] and other polyphenols [sesamin (lignan) or chlorogenic acid (phenolic acid)] (Loke et al., 2010). Flavonols may protect against atherosclerosis by preventing one or several processes involved in disease progression, such as oxidative stress, inflammation, and endothelial dysfunction. Most studies have shown that quercetin has no beneficial effect on the plasma lipid profile. Thus, plasma LDL or HDL cholesterol is unchanged in ApoE knockout mice (Hayek et al., 1997), in rats fed with a high-fat high sucrose diet (Yamamoto and Oue, 2006) or in overweight humans with an ApoE3 phenotype and it may even reduce the HDL/LDL ratio in carriers of the ApoE4 (Egert et al., 2010). In contrast, it has been shown to reduce serum triglycerides and cholesterol in high cholesterol-fed rabbits (Kamada et al., 2005). Besides the effects on plasma lipids, quercetin inhibits the crucial steps in the development of atherosclerosis including the susceptibility of LDL to oxidation (Frankel et al., 1993; Hayek et al., 1997), the LDL-induced cytotoxicity (Negre-Salvayre and Salvayre, 1992) and the aortic fatty streak formation (Auger et al., 2005). Interestingly, quercetin metabolites accumulate in the human atherosclerotic lesions, but not in the normal aorta (Kawai et al., 2008). Quercetin also significantly reduced aortic F2-isoprostane, vascular superoxide, vascular leukotriene B4, and plasma-sP-selectin concentrations; and augmented NO.

Quercetin has been shown to reduce serum triglycerides and cholesterol in high cholesterol-fed rabbits (Kamada et al., 2005). Besides the effects on plasma lipids, quercetin inhibits the crucial steps in the development of atherosclerosis including the susceptibility of LDL to oxidation (Frankel et al., 1993; Hayek et al., 1997), the LDL-induced cytotoxicity (Negre-Salvayre and Salvayre, 1992) and the aortic fatty streak formation (Auger et al., 2005). Interestingly, quercetin metabolites accumulate in the human atherosclerotic lesions, but not in the normal aorta (Kawai et al., 2008). Quercetin also significantly reduced aortic F2-isoprostane, vascular superoxide, vascular leukotriene B4, and plasma-sP-selectin concentrations; and augmented NO and heme oxygenase-1 in ApoE−/− mice (Loke et al., 2010). Adhesion molecules and matrix metalloproteinases are key proteins for several processes involved in atherosclerotic plaque formation such as infiltration of inflammatory cells. Quercetin was able to reduce TNF-α-induced upregulation of the adhesion molecules VCAM-1, ICAM-1 and MCP-1 at both the protein and mRNA level in human endothelial and vascular smooth muscle cells. However the quercetin metabolites, quercetin 3′-sulfate, quercetin 3-glucuronide and 3′-methylquercetin 3-glucuronide were almost without effect (Tribolo et al., 2008; Winterbone et al., 2009). The inhibitory effect on ICAM-1 expression occurs through a down-regulation of the JNK/AP-1 pathway (Kobuchi et al., 1999). In addition, quercetin can also preserve human serum paraoxonase (PON1) activity (Aviram et al., 1999) and upregulate its expression (Gong et al., 2009), an additional mechanism by which it can protect LDL from oxidation and play a protective role in atherosclerosis. The effects of isolated flavonols on the development of atherosclerosis in humans have not been addressed.

The underlying molecular mechanisms by which quercetin may antagonize inflammatory gene expression have not yet been fully elucidated. Quercetin and other flavonoids inhibit TNF-α production as well as iNOS expression and NO production in LPS-activated macrophages, an effect that has been associated with the inhibition of the NF-κB pathway, through inhibition of IκB-α phosphorylation (Comalada et al., 2006). Recently, the anti-inflammatory properties of quercetin and isorhamnetin in RAW264.7 macrophages were also accompanied by an increase in hemeoxygenase 1 protein levels, a downstream target of the transcription factor Nrf2, known to antagonize chronic inflammation (Boesch-Saadatmandi et al., 2010). Furthermore, proinflammatory microRNA-155 was down-regulated by quercetin and isorhamnetin but not by quercetin-3-glucuronide.

6. Flavonols, insulin resistance and obesity

Insulin resistance, defined as an attenuated or inadequate response to a given amount of insulin, is associated with a wide variety of conditions including obesity, type 2 diabetes, essential hypertension, cardiovascular disease, polycystic ovary syndrome, non-alcoholic fatty liver, breast cancer and acquired immune deficiency syndrome. Reciprocal relationships between endothelial dysfunction, insulin resistance, obesity and hypertension may help coupling hemodynamic and metabolic abnormalities observed in these important interrelated public health problems (Kim et al., 2006).

6.1. Obesity

Obesity arises from an imbalance in energy intake and energy expenditure that leads to the pathological growth of adipocytes. It is induced by the hypertrophy of adipocytes and the generation of new adipocytes from precursor cells. The exposure of 3T3-L1 preadipocytes to quercetin resulted in attenuated adipogenesis and decreased expression of adipogenesis-related factors and enzymes. Treatment of 3T3-L1 adipocytes with quercetin resulted in the induction of apoptosis and a concomitant decrease in ERK and JNK phosphorylation (Ahn et al., 2008; Yang et al., 2008).

New prevention and treatment options for obesity and type 2 diabetes could be based on strategies to dampen or inhibit fat absorption, cholesterol absorption, and intestinal catabolism of complex carbohydrates. Emerging evidence indicates that apical or luminal facing-facilitated glucose transporter 2 (GLUT2) is a major pathway of sugar absorption, and therefore an attractive target of such potential agents (Kellett and Brot-Laroche, 2005). Robust noncompetitive inhibition of glucose and fructose transport by GLUT2 expressed in Xenopus laevis oocytes was produced by the flavonols quercetin, myricetin, fisetin and its glucoside precursor isorquercitrin. The two other major intestinal sugar transporters, GLUT5 and SGLT1, were unaffected by flavonoids. Sugar transport by GLUT2 overexpressed in pituitary cells and naturally present in Caco-2E intestinal cells was similarly inhibited by quercetin (Kwon et al., 2007). Two key benefits could accrue: reduction of postprandial hyperglycemia in diabetic subjects and in subjects with mild glucose intolerance; and reduction of the total amount of glucose absorbed as a caloric and weight reduction strategy. Because quercetin might act as a potent luminal inhibitor of sugar absorption, flavonols might show promise as new pharmacologic agents in obesity.

However, when quercetin was tested in obese rodents and humans, its impact in body weight is unclear. In obese Zucker rats, daily oral administration for 10 weeks of 2 or 10 mg/kg of quercetin decreased body weight gain, only at the higher dose (Rivera et al., 2008b). Similarly, a reduced body weight gain was observed only at high doses of quercetin (0.2% and 0.5% in...
the diet) in rats on a high-fat high-sucrose diet (Yamamoto and Oue, 2006). In a model of diet-induced obesity in mice, dietary supplementation with a high dose of quercetin (0.8% of the diet) produces transient increases in energy expenditure that is not detected after 8 weeks on the diet (Stewart et al., 2008). Likewise, overweight-obese subject receiving 150 mg/d of quercetin for 6 weeks had no significant changes in the parameters of nutritional status including body weight, waist circumference, fat mass and fat-free mass (Egert et al., 2010).

6.2. Insulin resistance

Insulin resistance results from a complex interplay between nutrient overload, systemic fatty acids excess, inflammation of the adipose tissue, endoplasmic reticulum and oxidative stress (Hotamisligil, 2006) and hypoxia of the adipose tissue (Regazzetti et al., 2009). The action of insulin is initiated by its binding to the insulin receptor, followed by the autophosphorylation and phosphorylation of insulin receptor substrates (IRS) and a complex cascade of kinases and mediators (Sesti, 2006). These include the p85 regulatory subunit of phosphatidylinositol 3-kinase (PI3-K), phosphatidylinositol 3,4,5-trisphosphate (PIP3), phosphoinositide-dependent protein kinase and downstream protein kinase B/Akt as well as the atypical protein kinase C isoforms $\xi$ and $\lambda$ (PKC) (Stump et al., 2006). Both atypical PKC$\xi$ and Akt are important in mediating glucose transport in muscle by allowing translocation of GLUT4 to the sarcolemma to facilitate glucose entry into the cell (Ishiki and Klip, 2005). Accumulation of lipid metabolites as a consequence of alterations in fatty acid metabolism can have a profound impact on insulin signaling. Accumulation of lipid intermediates such as triacylglycerol, diacylglycerol, and ceramide is known to activate kinases such as JNK-AP-1, IKK-NF-kB and PKC inhibiting insulin action which serves as a negative feedback mechanism (Yu et al., 2002). Current pharmacological approaches to treat insulin resistance and type 2 diabetes include glitazones (agonists of peroxisome proliferator-agonist receptor gamma, PPAR$\gamma$), metformin (an activator of AMP-activated protein kinase, AMPK), sulphonylureas (ATP-dependent potassium channel blockers), acarbose ($\alpha$-glucosidase inhibitor), amylin analogs, incretin mimetics and dipeptidyl-peptidase 4 inhibitors (Rodbard et al., 2007).

As mentioned above, a potential mechanism by which quercetin may be beneficial in insulin resistance and type 2 diabetes is by inhibition of intestinal glucose transporters. In addition, quercetin also inhibits alpha-glucosidase (Li et al., 2009) preventing the intestinal digestion of carbohydrates more potently than acarbose which may also help to reduce postprandial hyperglycemia.

Quercetin and related flavonols have been reported to inhibit (Nomura et al., 2008; Strobel et al., 2005) or to increase (Fang et al., 2008) insulin-induced glucose uptake in adipocytes. These opposed actions may be explained because flavonols, as wide spectrum protein kinase inhibitors, have been described to inhibit the activity of both the kinases involved in insulin signaling and the kinases involved in the development of insulin resistance in several tissues (Dias et al., 2005; Granado-Serrano et al., 2010; Perez-Vizcaino et al., 2006a). In addition, the inhibitory effect of quercetin and myricetin on the insulin-stimulated uptake of methyglycose by adipocytes has been related to a transport inhibition mechanism in which flavonoids interact directly and PPAR$\gamma$, rather than by a mechanism related to protein-kinases and insulin signaling inhibition (Strobel et al., 2005). On the other side, increased glucose uptake may also be related to an interaction with PPAR$\gamma$ receptors. Kaempferol and quercetin served as weak partial agonists in the PPAR$\gamma$ reporter gene assay, but could not induce differentiation of 3T3-L1 preadipocytes as traditional PPAR$\gamma$ agonists (Fang et al., 2008). When added together with the PPAR$\gamma$ agonist rosiglitazone to 3T3-L1 preadipocytes, they could inhibit 3T3-L1 differentiation. Competitive ligand-binding assay confirmed that kaempferol and quercetin could compete with rosiglitazone at the same binding pocket site as PPAR$\gamma$.

AMP-activated protein kinase (AMPK), a member of a metabolite-sensing protein kinase family, also regulates glucose transport in skeletal muscle (Bergeron et al., 1999; Fryer et al., 2002). Since skeletal muscle accounts for disposal of approximately 80% of an oral glucose load and type 2 diabetes is associated with reduced muscle glucose disposal, AMPK may be critical in the control of whole body glucose homeostasis and perhaps exercise capacity. Quercetin exposure up-regulates the levels of phosphorylated AMPK and its substrate, acetyl-CoA carboxylase (ACC). Quercetin and other flavonoids can activate AMPK in HepG2 cells through the activation of the sirtuin analog SIRT1 (Suchankova et al., 2009). Moreover, in C2C12 skeletal muscle cells, quercetin enhanced glucose uptake in the absence of insulin which was related to AMPK activation (Eid et al., 2010).

The in vivo studies with flavonoids on insulin resistance also yielded conflicting results. In the obese Zucker rats, daily oral administration for 10 weeks of 2 or 10 mg/kg of quercetin, reduced dyslipidemia, insulin resistance and hypertension (Rivera et al., 2008b). The release of adipocytokines (leptin, resistin, plasminogen activator inhibitor type 1, and adiponectin) as well as inflammatory cytokines (TNF-$\alpha$, interleukin-1 and 6 and MCP-1), critically involved in insulin resistance and chronic inflammation, were also measured. Quercetin decreased both production of TNF-$\alpha$ and proinflammatory INOS expression by the visceral adipose tissue, and increased the plasma concentration of adiponectin (Rivera et al., 2008b). Moreover, dietary quercetin also reduced circulating markers of inflammation (interferon-$\gamma$, interleukin-1$\alpha$, and interleukin-4) in diet-induced models of obesity (Stewart et al., 2008). Stewart et al. (2008), in contrast, show that diet-induced insulin resistance in mice was not ameliorated by dietary quercetin. Similarly, in SHR rats which are not only genetically hypertensive but also show insulin resistance (Reaven and Chang, 1991), we found that the oral glucose tolerance test, the homeostatic model assessment of insulin resistance, the total cholesterol and triglycerides were unaffected by quercetin (Romero et al., 2010).

Oxidative stress generation impairs pancreatic $\beta$-cell insulin secretion (Bast et al., 2002). Flavonols may preserve $\beta$-cell function by reducing oxidative stress-induced tissue damage and therefore protect against the progression of insulin resistance to type 2 diabetes. In fact, quercetin, the main dietary flavonol, prevents and protects streptozotocin-induced oxidative
stress and β-cell damage in rat pancreas (Coskun et al., 2005) and decreased blood glucose concentration in both alloxan- and streptozotocin-induced diabetic rats (Coskun et al., 2005; Kobori et al., 2009; Nuralievli and Avezov, 1992), two models of type 1 diabetes.

A recent study (Liang et al., 2009a) showed that the gestational diabetes mellitus-induced placental oxidative stress in mice were significantly mitigated by quercetin supplementation. Results from this report also revealed that quercetin partially decreased maternal hyperglycemia and hyperinsulinemia, and offer additional information about preventive and therapeutic management of gestational diabetes mellitus, a commonly encountered disorder of mid to late pregnancy.

Despite the crucial role of insulin resistance in the development of atherosclerosis and cardiovascular risk, there are not human studies addressing the role of chronic flavonols supplementation as a therapeutic approach to treat insulin resistance. There are two epidemiological studies analyzing the relationship between flavonol intake and type 2 diabetes which again yielded conflicting results. A trend toward a reduction in risk of type 2 diabetes was associated with higher quercetin and myricetin intakes in the Finish study (Knekt et al., 2002) while in a large study of American women free of cardiovascular disease, high intake of flavonols and flavones was not significantly associated with risk of type 2 diabetes and insulin resistance (Song et al., 2005).

7. Flavonols and myocardial ischemia

Chronic coronary disease and the acute coronary syndromes involve multiple alterations in vascular reactivity, vascular structure, and interactions of the vessel wall with circulating blood elements.

Hypertension and atherosclerosis are the main risk factors for myocardial infarction and an immense body of evidence indicates that reduction of LDL-cholesterol and atherosclerotic lesions and blood pressure produces a dramatic decline in the risk of coronary disease (Turnbull, 2003). Additionally, endothelial dysfunction is an independent prognostic factor for myocardial infarction (Schachinger et al., 2000; Widlansky et al., 2003). Flavonols by preventing hypertension, atherosclerosis and endothelial dysfunction, as reviewed above, may protect the coronary vessels in the long term.

Most acute coronary events result from a rupture in the atherosclerotic plaque, thrombus formation and the subsequent myocardial ischemia. Degradation of the interstitial collagen conferring biomechanical strength to the plaque fibrous cap by matrix metalloproteinases (MMPs) appears to be involved in the plaque instability and its rupture. Quercetin reduces the expression of matrix metalloproteinases (MMP-2 and MMP-9) (Huang et al., 1999) and may help in stabilizing the atherosclerotic plaque (Motoyama et al., 2009). Coronary vasospasm may also contribute to acute impaired arterial flow. Flavonols by their platelet antiaggregant and vasodilator effects, as reviewed above, may also provide additional protective benefit in the acute phase. During the ischemic event and the eventual post-ischemic reperfusion there is an acute inflammatory process with the release of multiple cytokines and reactive oxygen species. Post-ischemic reperfusion occurring in coronary diseases is generally associated with a reduction of endogenous NO production resulting from endothelial dysfunction and tissue damage linked to neutrophil infiltration. Experimental studies in animal models in which ischemia is acutely induced by coronary artery ligation or infusion of isoproterenol have shown that quercetin reduces the contractile dysfunction of the heart, the infarct size and the pattern of protein expression changes (including iNOS and NOX2) induced by cardiac ischemia (Annapurna et al., 2009; Brookes et al., 2002; Punithavathi and Prince, 2010; Wan et al., 2009). These effects may be observed following the oral intake of quercetin in vivo and ex vivo. Most reports associate the protective effect on the heart to the anti-oxidants effects of quercetin. The capacity of flavonoids to protect NO probably plays a crucial role to prevent ischemia.

In the seminal epidemiological report (Hertog et al., 1993), flavonoid intake (analyzed in tertiles) was strongly inversely associated with mortality from coronary heart disease [relative risk 0.42 (95% CI 0.20–0.88)] after adjustment for known risk factors and other dietary components. An inverse relation with incidence of myocardial infarction, which was of borderline

![Fig. 7. Prospective cohort studies of flavonoid and coronary heart disease. Risk ratios compare top and bottom thirds of baseline measurements. Black squares indicate the risk ratio in each study, with the square size proportional to the number of CHD fatal events and the horizontal lines representing 95% CI. The combined risk ratio and its 95% CI is denoted by the black diamond. Reprinted with permission (Huxley and Neil, 2003).](image-url)
significance was also noted. A number of similar epidemiological studies followed. The meta-analysis of this prospective cohort studies concluded that the individuals in the top third of dietary flavonol intake are associated with a reduced risk [0.80 (95% CI 0.69–0.93)] of mortality from coronary heart disease as compared with those in the bottom third (Fig. 7) (Huxley and Neil, 2003).

8. Flavonols and stroke

The primary cause of stroke is an interruption of cerebral blood flow occurring during vascular obstruction by thromboembolism or local thrombosis. The pathophysiological processes in stroke are complex and depend on the severity, duration and localization of the ischemic damage in the brain. The main risk factors that lead to occurrence of stroke are hypertension, atherosclerosis, LDL-cholesterol, diabetes and atrial fibrillation. Flavonoids have been proposed to be effective both as preventive agents and as treatment options in the acute phase of stroke (Simonyi et al., 2005). As described above, flavonols prevent endothelial dysfunction, atherosclerosis, hypertension and possibly thrombosis, all potential mechanism to prevent strokes. With regard to acute treatment, flavonols may act on different phases of stroke. For the acute phase, flavonols improve cerebral blood flow, prevent platelet aggregation and thrombosis, reduce excitotoxicity and inhibit oxidative stress. For the intermediate phase, flavonols reduce inflammation and protect endothelial integrity. For the late phase, flavonols interfere with ischemia induced cell death mechanisms such as apoptosis and necrosis.

Quercetin and kaempferol, in in vitro conditions, inhibit excitotoxicity. In fact, both agents significantly reduced neuronal death caused by kainate plus N-methyl-D-aspartate (Silva et al., 2008). The observed neuroprotection was correlated with prevention of delayed calcium deregulation and with the maintenance of mitochondrial transmembrane electric potential. These flavonols reduced mitochondrial lipid peroxidation and loss of mitochondrial transmembrane electric potential caused by oxidative stress induced by ADP plus iron. Thus, the neuroprotective action induced by quercetin and kaempferol was mainly attributed to its anti-oxidant effects (Silva et al., 2008). Moreover, quercetin abolished hypoxia-induced increase in types 1 and 2 IP3 receptors on cerebellar granular cells of rat, and regulates intracellular calcium (Jurkovicova et al., 2007). Quercetin also effectively protected cerebellar granule neurons or mesencephalic dopamine neurons from death induced by oxidative stress (Echeverry et al., 2010; Mercer et al., 2005).

In vivo, quercetin has been also reported to be able to scavenge superoxide anions released during reperfusion after forebrain ischemia using a four-vessel occlusion model in rats (Shutenko et al., 1999). In another study, the reduction in global ischemia-induced neuronal damage was attributed to inhibition of MMP-9 activity (Cho et al., 2006). However, in a model of neuronal oxidative damage in vivo by unilateral infusion of 6-OHDA into the medial forebrain bundle (Zbarsky et al., 2005), quercetin or fisetin had no effect on the loss of tyrosine hydroxylase-positive cells in the substantia nigra. The lack of ability of quercetin in some in vivo models despite the in vitro neuroprotective effect on damage induced by different stimuli, is probably due to difficulties in crossing the blood–brain barrier and to penetrate into the brain. Moreover, quercetin metabolites seem to be less neuroprotective and penetrate the blood–brain barrier less efficiently than the aglycone. However, increased blood–brain barrier permeability may occur under inflammatory conditions as occur in stroke which would facilitate quercetin brain penetration. When flavonoids were administered in lecithin preparation to facilitate the crossing of the blood–brain barrier, treatment of permanent focal ischemia with this lecithin/quercetin preparation decreased lesion volume (Dajas et al., 2003). The protective effect against ischemic lesion was demonstrated by a significant increase in numbers of cells in striatum and cortex, together with a partial reversal of motor deficits. Moreover, reduced glutation (GSH) levels decreased after ischemia in the ipsilateral striatum and cortex, and the liposomal quercetin preparation reversed these effects 24 h after the permanent middle cerebral arterial occlusion (Rivera et al., 2008a).

Chronic administration of quercetin has anti-inflammatory properties in the brain. In fact, in lipopolysaccharide (LPS)-treated mice, quercetin inhibits the expression of proinflammatory enzymes COX2 and iNOS, reversing LPS-induced memory deficits (Patil et al., 2003). In BV-2 microglial cells stimulated by LPS/interferon-gamma, quercetin produces an inhibitory effect on iNOS and NO production. The anti-inflammatory action of quercetin may be attributable to its raft disrupting and anti-oxidant effects. These distinct mechanisms work in synergy to down-regulate iNOS expression and NO production (Kao et al., 2010). Sharma et al. (2007) showed that flavonoids confer protection against IL-1beta induced astrocyte mediated neuronal damage by: (i) enhancing the potential of activated astrocytes to detoxify free radical (superoxide dismutase-1 and thioredoxin-mediators), (ii) reducing the expression of proinflammatory cytokines (IL-6) and chemokines (IL-8, IP-10, MCP-1 and RANTES), and (iii) modulating expression of mediators associated with enhanced physiological activity of astrocyte in response to injury.

There are several prospective epidemiological studies analyzing the relationship between flavonol intake and stroke. The Zutphen study reported an inverse association of stroke with increasing dietary flavonoid consumption (mainly quercetin) after adjustment for several confounders, including vitamin intake (Keli et al., 1996). Later studies (Knekt et al., 2000; Yochum et al., 1999) carried out in large cohorts in Finland and USA, respectively, showed that the relative risk of cerebrovascular disease was similar among subjects with high or low intake of flavonols. Thus, the authors concluded that quercetin intake is not associated with cerebrovascular disease. However, very recently, a meta-analysis of six prospective cohort studies (Hollman et al., 2010) found that a high intake of flavonols compared with a low intake was inversely associated with nonfatal and fatal stroke with a pooled relative risk of 0.80 (95% CI: 0.65, 0.98). It was concluded that flavonols may reduce stroke risk, even when publication bias was suspected.
9. Conclusions

Flavonols, and specially quercetin, are widely distributed in plants and are present in considerable amounts in fruits and vegetables. In addition to its anti-oxidant effect, there is an impressive number of enzymes whose activity is modulated (mostly inhibited) by quercetin. Thus, it can be predicted that a huge number of biochemical signaling pathways and, therefore, physiological and pathological processes, can be affected by this flavonol. It is surprising that quercetin is still widely regarded just as an anti-oxidant and even more astonishing that it is often used as a pharmacological tool to “specifically” inhibit a given enzyme. It can potentially interact with many of the molecular targets known to be involved in the pathophysiology of ischemic heart disease and stroke. Thus, it may act by multiple mechanisms operating both in the long term prevention and in the acute phase of cardiovascular events (Fig. 8). These multiple interactions often go in the right direction and explain the protective effects in cardiovascular disease but occasionally result in detrimental effects.

To summarize, there is solid evidence that, in vitro, quercetin and related flavonols exert: (1) endothelium-independent vasodilator effects, (2) protective effect on nitric oxide and endothelial function under conditions of oxidative stress, (3) platelet antiaggregant effects, (4) inhibition of LDL oxidation, (5) reduction of adhesion molecules and other inflammatory markers and (6) prevention of neuronal oxidative and inflammatory damage. The in vitro effects regarding NO production in healthy vessels and glucose uptake in adipocytes are controversial. The metabolites of quercetin show partial protective effects on endothelial function and LDL oxidation. In animal models of disease, quercetin produces undisputed antihypertensive and antiatherogenic effects, prevents endothelial dysfunction and protects the myocardium from ischemic damage. It has no clear effects on serum lipid profile and on insulin resistance and at high doses it may also reduce obesity. Human intervention trials with isolated flavonols demonstrate an antihypertensive effect while no data is available on endothelial function, insulin resistance or atherosclerosis. Some evidence also points to differential effects depending on the genetic background of the patients. The meta-analysis of epidemiological studies show an inverse association between flavonol (together with flavone) intake and coronary heart disease and stroke. Therefore, although there is still no solid proof, a substantial body of evidence suggests that quercetin may prevent the most common forms of cardiovascular disease contributing to the protective effects afforded by fruits and vegetables.

Acknowledgements

The authors research is funded by a Grant from the Spanish Ministerio de Ciencia y Tecnología (AGL2007-66108, SAF2008-03948 and Red HERACLES RD06/0009) and from Junta de Andalucía (Proyecto de Excelencia, P06-CTS-01555).

References


